검색어 : 통합검색[Partridge Ian]
총 174건 중 174건 출력
, 15/18 페이지
-
141
- Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer : A Correlative Analysis of the CALGB 40601 and PAMELA Trials
- Fernandez-Martinez, Aranzazu; Pascual, Tomá s; Singh, Baljit; Nuciforo, Paolo; Rashid, Naim U.; Ballman, Karla V.; Campbell, Jordan D.; Hoadley, Katherine A.; Spears, Patricia A.; Pare, Laia; Brasó -Maristany, Fara; Chic, Nuria; Krop, Ian; Partridge, Ann; Corté s, Javier; Llombart-Cussac, Antonio; Prat, Aleix; Perou, Charles M.; Carey, Lisa A.; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Department of Pathology, White Plains Hospital, White Plains, New York; Molecular Oncology Laboratory, Vall d’Hebron Institute of Oncology, Barcelona, Spain; Department of Biostatistics, University of North Carolina, Chapel Hill; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill; Reveal Genomics, Barcelona, Spain; Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Department of Medical Oncology, Hospital Clí nic de Barcelona, Barcelona,; (JAMA oncology, v.9, 2023, pp.490-499)
-
142
- A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer
- Waks, Adrienne G.; Desai, Neelam V.; Li, Tianyu; Poorvu, Philip D.; Partridge, Ann H.; Sinclair, Natalie; Spring, Laura M.; Faggen, Meredith; Constantine, Michael; Metzger, Otto; Alberti, Jillian; Deane, Julia; Rosenberg, Shoshana M.; Frank, Elizabeth; Tolaney, Sara M.; Krop, Ian E.; Tung, Nadine M.; Tayob, Nabihah; King, Tari A.; Mittendorf, Elizabeth A.; Winer, Eric P.; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA; Harvard Medical School, Boston, MA USA; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA USA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA; Harvard Medical School, Boston, MA USA; Harvard Medical School, Boston, MA USA; Harvard Medical School, Boston, MA USA; Harvard Medical School, Boston, MA USA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA; Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA; Harvard Medical School, Boston, MA USA; Harvard Medical School, Bost; (NPJ breast cancer, v.8, 2022, pp.63)
-
143
- Preclinical Toxicology Supply for a Complex API Enabled by Asymmetric Catalysis and Rapid Chemical Development: IL-17A Inhibitor LY3509754
-
Beauchamp, Thomas J.;
Cole, Kevin P.;
Broughton, Howard B.;
Coates, David A.;
Cumming, Graham Robert;
de Diego, Jose Eugenio;
Frimpong, Kwame;
Gutierrez, Julio;
Holloway, William;
Hotham, Ian;
Jones, Spencer;
Kaoudi, Talbi;
Lander, Peter;
Levinson, Adam M.;
Lu, Yu;
Lugar, Charles;
Partridge, Katherine;
Ruble, J. Craig;
Saouane, Sofiane;
Ummaneni, Narasimha Rao;
Vandeveer, H. George;
Watson, Brian;
Centro de Investigació
n Lilly S.A., Avda. de la Industria , 30 , 28108 Alcobendas , Madrid , Spain;
Synthetic Molecule Design and Development , Eli Lilly and Company , Lilly Technology Center North , Indianapolis , Indiana 46221 , United States;
Centro de Investigació
n Lilly S.A., Avda. de la Industria , 30 , 28108 Alcobendas , Madrid , Spain;
Centro de Investigació
n Lilly S.A., Avda. de la Industria , 30 , 28108 Alcobendas , Madrid , Spain;
Discovery Research Chemistry and Technologies, Eli Lilly and Co , Indianapolis , Indiana 46285 , United States;
Albany Molecular Research Inc., Now Curia , 24 Corporate Circle , Albany , New York 12203 , United States;
Discovery Research Chemistry and Technologies, Eli Lilly and Co , Indianapolis , Indiana 46285 , United States
United; (Organic process research & development, v.29, 2025, pp.889-908)
-
144
- Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC).
- Tolaney, Sara M.; Barry, William Thomas; Guo, Hao; Dillon, Deborah; Dang, Chau T.; Yardley, Denise A.; Moy, Beverly; Marcom, P. Kelly; Albain, Kathy S.; Rugo, Hope S.; Ellis, Matthew James; Shapira, Iuliana; Wolff, Antonio C.; Carey, Lisa A.; Overmoyer, Beth; Partridge, Ann H.; Hudis, Clifford A.; Krop, Ian E.; Burstein, Harold J.; Winer, Eric P.; Dana-Farber Cancer Institute, Boston, MA; ; Dana-Farber Cancer Institute, Boston, MA; ; Dana-Farber Cancer Institute, Boston, MA; ; Brigham and Women's Hospital, Boston, MA; ; Memorial Sloan-Kettering Cancer Center, New York, NY; ; Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; ; Massachusetts General Hospital Cancer Center, Boston, MA; ; Duke University Medical Center, Durham, NC; ; Loyola University Chicago Stritch School of Medicine, Cardinal Bernardin Cancer Center, Maywood, IL; ; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; ; Lester and Sue Smith Breast Center, Baylor Clinic, Baylor College of Medicine, Houston, TX; ; Albert Einstein College of Medicine - Jacobi Medical Center, Bronx, NY; ; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; ; University of North Carolina, Chapel Hill, NC; ; Dana-Farber Cancer Institute, Boston, MA; ; Dana-Farber Cancer Institute, Adult Su; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.35, 2017, pp.511-511)
-
145
- Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).
- Tolaney, Sara M.; Barroso-Sousa, Romualdo; Keenan, Tanya; Trippa, Lorenzo; Hu, Jiani; Luis, Ines Maria Vaz Duarte; Wulf, Gerburg M.; Spring, Laura; Sinclair, Natalie Faye; Andrews, Chelsea; Pittenger, Jessica Demeo; Richardson, Edward T.; Dillon, Deborah; Lin, Nancy U.; Overmoyer, Beth; Partridge, Ann H.; VanAllen, Eliezer; Mittendorf, Elizabeth A.; Winer, Eric P.; Krop, Ian E.; Dana-Farber Cancer Institute, Boston, MA; ; Instituto Do Cancer Do Estado De Sã o Paulo, Sã o Paulo, Brazil; ; Massachusetts General Hospital, Boston, MA; ; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA; ; Dana-Farber Cancer Institute, Boston, MA; ; Dana-Farber Cancer Institute, Boston, MA; ; Beth Israel Deaconess Medcl Ctr, Boston, MA; ; Massachusetts General Hospital, Boston, MA; ; Dana-Farber Cancer Institute, Milford, MA; ; Dana-Farber Cancer Institute, Boston, MA; ; Dana-Farber Cancer Institute, Boston, MA; ; Dana-Farber Cancer Institute, Boston, MA; ; Brigham and Women's Hospital, Boston, MA; ; Dana-Farber Cancer Institute, Boston, MA; ; Dana-Farber Cancer Institute, Boston, MA; ; Dana-Farber Cancer Institute, Boston, MA; ; Dana-Farber Cancer Institute, Boston, MA; ; Dana-Farber/Brigham and Women’s Cancer Center, Boston, MA; ; Dana-Farber Cancer Institute, Boston, MA; ; Dana-Farber Cancer Institute, Boston, MA; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.37, 2019, pp.1004-1004)
-
146
- Book Reviews
- Flanagan, Kieran; Keenan, William; Kamsteeg, Frans H.; Deacy, Chris; Partridge, Christopher; Bellous, Joyce E.; Beyer, Peter; Spickard, James V.; Reader, Ian; Amarasingam, Amarnath; Hector, Susan; Dinter, Astrid; Stephens, Piers H. G.; Althaus-reid, Marcella; De michelis, Elizabeth; hole, Elizabeth Asa; Morgan, Peggy; Barot, Rohit; Spickard, James V.; Sjö qvist, Madeleine Sultá n; Ramey, Steven W.; Warburg, Margit; Department of Sociology, University of Bristol, Bristol, UK; School of Social Sciences, Nottingham Trent University, Nottingham, UK; Faculty of Social Sciences, Vrije Universiteit, Amsterdam, The Netherlands; Applied Theology, University of Kent, Canterbury, UK; Department of Religious Studies, Lancaster University, Lancaster, UK; McMaster Divinity College, Hamilton, Ontario, Canada; Department of Religious Studies, University of Ottawa, Ottawa, Ontario, Canada; Department of Sociology & Anthropology, University of Redlands, Redlands, California, USA; School of Languages, Linguistics and Cultures, University of Manchester, Manchester, UK; Department of Religion and Culture, Wilfrid Laurier University, Waterloo, Ontario, Canada; Westminster Institute of Education, Oxford Brookes University, Oxford, UK; Department of Protestant Theology, Johann Wolfgang Goethe-University, Frankfurt a.M., Germany; Lyman Briggs College, Michigan State University, Michigan, USA; School of Divin; (Journal of contemporary religion, v.22, 2007, pp.391-433)
-
147
- Assessing the Mitochondrial Membrane Potential in Cells and In Vivo using Targeted Click Chemistry and Mass Spectrometry
- Logan, Angela; Pell, Victoria R.; Shaffer, Karl J.; Evans, Cameron; Stanley, Nathan J.; Robb, Ellen L.; Prime, Tracy A.; Chouchani, Edward T.; Cochemé , Helena M.; Fearnley, Ian M.; Vidoni, Sara; James, Andrew M.; Porteous, Carolyn M.; Partridge, Linda; Krieg, Thomas; Smith, Robin A.J.; Murphy, Michael P.; Medical Research Council Mitochondrial Biology Unit, Hills Road, Cambridge CB2 0XY, UK; Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 2QQ, UK; Department of Chemistry, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand; Department of Chemistry, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand; Department of Chemistry, University of Otago, P.O. Box 56, Dunedin 9054, New Zealand; Medical Research Council Mitochondrial Biology Unit, Hills Road, Cambridge CB2 0XY, UK; Medical Research Council Mitochondrial Biology Unit, Hills Road, Cambridge CB2 0XY, UK; Medical Research Council Mitochondrial Biology Unit, Hills Road, Cambridge CB2 0XY, UK; Institute of Healthy Ageing, Department of Genetics, Evolution, and Environment, University College London, Gower Street, London WC1E 6BT, UK; Medical Research Council Mitochondrial Biology Unit, Hills Road, Cambridge CB2 0XY, UK; Medical Research Council Mitochon; (Cell metabolism, v.23, 2016, pp.379-385)
-
148
- An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations : Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice
- Reddel, Helen K.; Taylor, D. Robin; Bateman, Eric D.; Boulet, Louis-Philippe; Boushey, Homer A.; Busse, William W.; Casale, Thomas B.; Chanez, Pascal; Enright, Paul L.; Gibson, Peter G.; de Jongste, Johan C.; Kerstjens, Huib A. M.; Lazarus, Stephen C.; Levy, Mark L.; O'Byrne, Paul M.; Partridge, Martyn R.; Pavord, Ian D.; Sears, Malcolm R.; Sterk, Peter J.; Stoloff, Stuart W.; Sullivan, Sean D.; Szefler, Stanley J.; Thomas, Mike D.; Wenzel, Sally E.; ; (American journal of respiratory and critical care medicine : an official journal of the American Thoracic Society, medical section of the American Lung Association, v.180, 2009, pp.59-99)
-
149
- Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
- Tolaney, Sara M.; Guo, Hao; Pernas, Sonia; Barry, William T.; Dillon, Deborah A.; Ritterhouse, Lauren; Schneider, Bryan P.; Shen, Fei; Fuhrman, Kit; Baltay, Michele; Dang, Chau T.; Yardley, Denise A.; Moy, Beverly; Marcom, P. Kelly; Albain, Kathy S.; Rugo, Hope S.; Ellis, Mathew J.; Shapira, Iuliana; Wolff, Antonio C.; Carey, Lisa A.; Overmoyer, Beth; Partridge, Ann H.; Hudis, Clifford A.; Krop, Ian E.; Burstein, Harold J.; Winer, Eric P.; Dana-Farber Cancer Institute, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Dana-Farber Cancer Institute, Boston, MA; Brigham and Women’s Hospital, Boston, MA; Brigham and Women’s Hospital, Boston, MA; Indiana University School of Medicine, Indianapolis, IN; Indiana University School of Medicine, Indianapolis, IN; NanoString Technologies, Seattle, WA; Brigham and Women’s Hospital, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Sarah Cannon Cancer Center, Nashville, TN; Massachusetts General Hospital, Boston, MA; Duke Cancer Institute, Durham, NC; Loyola University Chicago Stritch School of Medicine, Maywood, IL; University of California, San Francisco, San Francisco, CA; Baylor Clinic Lester and Sue Smith Breast Center, Houston, TX; Hofstra North Shore-LIJ School of Medicine, New Hyde Park, NY; Johns Hopkins University, Baltimore, MD; University of North Carolina, Chapel Hill, NC; Dana-Farber; (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, v.37, 2019, pp.1868-1875)
-
150
- Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer
- Keenan, Tanya E.; Guerriero, Jennifer L.; Barroso-Sousa, Romualdo; Li, Tianyu; O’Meara, Tess; Giobbie-Hurder, Anita; Tayob, Nabihah; Hu, Jiani; Severgnini, Mariano; Agudo, Judith; Vaz-Luis, Ines; Anderson, Leilani; Attaya, Victoria; Park, Jihye; Conway, Jake; He, Meng Xiao; Reardon, Brendan; Shannon, Erin; Wulf, Gerburg; Spring, Laura M.; Jeselsohn, Rinath; Krop, Ian; Lin, Nancy U.; Partridge, Ann; Winer, Eric P.; Mittendorf, Elizabeth A.; Liu, David; Van Allen, Eliezer M.; Tolaney, Sara M.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA; Breast Tumor Immunology Laboratory, Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA USA; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Division of Biostatistics, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA USA; Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA USA; Medical Oncology Depar; (Nature communications, v.12, 2021, pp.5563)
QUICK MENU
